Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Thomssen

Showing results (51-60 of 71) with videos related to

Pageof 8
Sort By:
Anti-Cancer Drugs|August 13, 2005
Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBCG von Minckwitz, I Chernozemsky, L Sirakova, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2013
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patientsN Harbeck, M Schmitt, C Meisner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2008
Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trialM Schmidt, A Victor, D Bratzel, et al.
International Journal of Cancer|December 31, 2013
Breast cancer survival in Ethiopia: a cohort study of 1,070 womenE J Kantelhardt, P Zerche, A Mathewos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN studyJ Furlanetto, W Eiermann, F Marmé, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2017
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trialV Möbus, C Jackisch, H J Lück, et al.
Breast (Edinburgh, Scotland)|August 25, 2011
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trialJ Huober, P A Fasching, M Barsoum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patientsV Möbus, G von Minckwitz, C Jackisch, et al.
Oncology (Williston Park, N.Y.)|February 3, 2005
Anthracycline and trastuzumab in breast cancer treatmentM Untch, I Himsl, S Kahlert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2016
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc TrialO Gluz, C Liedtke, J Huober, et al.
Pageof 8

Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Anti-Cancer Drugs|August 13, 2005
Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBCG von Minckwitz, I Chernozemsky, L Sirakova, et al.
European Journal of Cancer (Oxford, England : 1990)|March 16, 2013
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patientsN Harbeck, M Schmitt, C Meisner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2008
Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trialM Schmidt, A Victor, D Bratzel, et al.
International Journal of Cancer|December 31, 2013
Breast cancer survival in Ethiopia: a cohort study of 1,070 womenE J Kantelhardt, P Zerche, A Mathewos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN studyJ Furlanetto, W Eiermann, F Marmé, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2017
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trialV Möbus, C Jackisch, H J Lück, et al.
Breast (Edinburgh, Scotland)|August 25, 2011
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trialJ Huober, P A Fasching, M Barsoum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 2, 2017
German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patientsV Möbus, G von Minckwitz, C Jackisch, et al.
Oncology (Williston Park, N.Y.)|February 3, 2005
Anthracycline and trastuzumab in breast cancer treatmentM Untch, I Himsl, S Kahlert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 30, 2016
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc TrialO Gluz, C Liedtke, J Huober, et al.
Pageof 8